Lantheus (NASDAQ:LNTH) Trading Down 5.7% – Here’s What Happened

Lantheus Holdings, Inc. (NASDAQ:LNTH) shares traded down 5.7% on Monday . The stock traded as low as $103.92 and last traded at $103.5780. Approximately 478,643 shares were traded during mid-day trading, a decline of 50% from the average daily volume of 960,882 shares. The stock had previously closed at $109.89.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on LNTH shares. Mizuho raised their target price on Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Jefferies Financial Group reissued a “buy” rating and issued a $110.00 price objective on shares of Lantheus in a research note on Tuesday, March 17th. William Blair restated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a report on Tuesday, May 26th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 price target on shares of Lantheus in a research report on Thursday, May 7th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Price Performance

The firm has a market cap of $6.76 billion, a P/E ratio of 25.10 and a beta of -0.06. The company has a fifty day moving average of $98.54 and a 200-day moving average of $81.62. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 4.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently made changes to their positions in LNTH. Versant Capital Management Inc grew its position in shares of Lantheus by 33.0% during the 2nd quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock valued at $65,000 after acquiring an additional 146 shares during the period. Empowered Funds LLC bought a new stake in shares of Lantheus during the 1st quarter valued at $909,000. Carmignac Gestion lifted its holdings in shares of Lantheus by 18.4% in the first quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock worth $100,729,000 after buying an additional 206,000 shares in the last quarter. Defilade Capital Management L.P. purchased a new stake in Lantheus in the 1st quarter worth approximately $18,917,000. Finally, Parallel Advisors LLC raised its position in shares of Lantheus by 95.9% in the first quarter. Parallel Advisors LLC now owns 1,060 shares of the medical equipment provider’s stock worth $80,000 after buying an additional 519 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.